AlgiPharma signs new license agreement with NTNU

/in

AlgiPharma signed a new license agreement securing exclusive the global rights for the OligoG patent portfolio from the Norwegian University of Science and Technology (NTNU) for all disease areas and medical applications, except non-inhalation treatment in oncology.

Yngvar P. Berg, CEO; yngvar.berg@algipharma.com

March 9, 2016

You might also like
AlgiPharma granted Orphan Drug designation by FDA
AlgiPharma in the News: GlobalNewswire and DelveInsight’s Business Report.
AlgiPharma awarded four year grant from Norwegian Research Council
AlgiPharma Announces $4 Million Award from Cystic Fibrosis Foundation Therapeutics to Advance Clinical Development of OligoG
Technology Strategy Board & Innovation Norway – Algiferm Project Success
The effect of alginate oligosaccharides on the mechanical properties of Gram-negative biofilms
AlgiPharma granted permission to start Phase II trials in Cystic Fibrosis
AlgiPharma awarded secured 2.700.000 NOK for joint UK/Norwegian innovation project